Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. has exhibited a significant commitment to advancing its clinical-stage programs, as evidenced by a rise in research and development expenses to $7.4 million, indicating a strategic expansion in infrastructure and clinical activities. The impressive early preclinical results of its product candidates, particularly the FSdC program which demonstrated enhanced regenerative capabilities compared to other fibroblast approaches, underscore the potential for substantial market differentiation in addressing chronic conditions with unmet medical needs. Furthermore, biomarker improvements associated with CYWC628, particularly in inflammatory response and tissue regeneration, suggest promising therapeutic benefits that may enhance patient outcomes and align with the growing demand for innovative regenerative therapies.

Bears say

FibroBiologics Inc operates within a significant global healthcare challenge related to burn injuries, with a market valued at approximately $2.55 billion, projected to grow to $3.35 billion by 2030. Despite the recognized need for advanced regenerative therapies to improve healing speed and tissue quality, the company's focus on fibroblast-based therapies may face challenges in clinical development, market acceptance, and competition. Furthermore, the reliance on a limited product pipeline, including candidates like CYWC628 and CYPS317, raises concerns regarding financial sustainability and the ability to capture market share in a competitive landscape.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.